Novo Nordisk A/S (NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of its ...

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

COPENHAGEN () -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the Danish ...

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in ...

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...